# OnCo record eflornithine (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/eflornithine/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "eflornithine" ;
  schema:name "Eflornithine (DFMO)"@en ;
  schema:description "Eflornithine (DFMO) is an old sleeping-sickness drug repurposed as the first oral maintenance therapy for high-risk neuroblastoma, approved in December 2023 to reduce relapse after immunotherapy."@en ;
  schema:url <https://onco.cc/drugs/eflornithine/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Eflornithine> ;
  owl:sameAs <http://www.wikidata.org/entity/Q424751> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Eflornithine> ;
  onco:status "approved" ;
  onco:modality "Small-molecule ornithine decarboxylase inhibitor" ;
  schema:alternateName "Iwilfin" ;
  onco:approval "US 2023: Maintenance to reduce relapse risk in high-risk neuroblastoma after ≥PR to prior therapy including anti-GD2" ;
  onco:cancers <https://onco.cc/cancers/neuroblastoma/>, <https://onco.cc/cancers/neuroblastoma-high-risk/> ;
  onco:companies <https://onco.cc/companies/us-worldmeds/> ;
  onco:terms <https://onco.cc/terms/mycn-amplification/> ;
  onco:trials <https://onco.cc/trials/nmtrc003/>, <https://onco.cc/trials/nct07287917/> .